Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
IRP1 deficiency alters mitochondrial metabolism and protects against metabolic syndrome pathologies
Wen Gu, Nicole Wilkinson, Carine Fillebeen, Darren M. Blackburn, Korin Sahinyan, Eric Bonneil, Tao Zhao, Zhi Luo, Vahab D. Soleimani, Vincent Richard, Christoph H. Borchers, Albert Koulman, Benjamin Jenkins, Bernhard Michalke, Hans Zischka, Judith Sailer, Vivek Venkataramani, Othon Iliopoulos, Gary Sweeney, Kostas Pantopoulos
Wen Gu, Nicole Wilkinson, Carine Fillebeen, Darren M. Blackburn, Korin Sahinyan, Eric Bonneil, Tao Zhao, Zhi Luo, Vahab D. Soleimani, Vincent Richard, Christoph H. Borchers, Albert Koulman, Benjamin Jenkins, Bernhard Michalke, Hans Zischka, Judith Sailer, Vivek Venkataramani, Othon Iliopoulos, Gary Sweeney, Kostas Pantopoulos
View: Text | PDF
Research Article Hepatology Metabolism

IRP1 deficiency alters mitochondrial metabolism and protects against metabolic syndrome pathologies

  • Text
  • PDF
Abstract

Iron regulatory protein 1 (IRP1) is a posttranscriptional regulator of cellular iron metabolism. In mice, loss of IRP1 causes polycythemia through translational de-repression of HIF2α mRNA, which increases renal erythropoietin production. Here, we show that Irp1–/– mice develop fasting hypoglycemia and are protected against high-fat diet–induced hyperglycemia and hepatic steatosis. Discovery-based proteomics of Irp1–/– livers revealed a mitochondrial dysfunction signature. Seahorse flux analysis in primary hepatocytes and differentiated skeletal muscle myotubes confirmed impaired respiratory capacity, with a shift from oxidative phosphorylation to glycolytic ATP production. This metabolic rewiring was associated with enhanced insulin sensitivity and increased glucose uptake in skeletal muscle. Under metabolic stress, IRP1 deficiency altered the redox balance of mitochondrial iron, resulting in inefficient energy production and accumulation of amino acids and metabolites in skeletal muscles, rendering them unavailable for hepatic gluconeogenesis. These findings identify IRP1 as a critical regulator of systemic energy homeostasis.

Authors

Wen Gu, Nicole Wilkinson, Carine Fillebeen, Darren M. Blackburn, Korin Sahinyan, Eric Bonneil, Tao Zhao, Zhi Luo, Vahab D. Soleimani, Vincent Richard, Christoph H. Borchers, Albert Koulman, Benjamin Jenkins, Bernhard Michalke, Hans Zischka, Judith Sailer, Vivek Venkataramani, Othon Iliopoulos, Gary Sweeney, Kostas Pantopoulos

×

Figure 6

IRP1 deficiency triggers metabolic reprogramming in mice fed high-fat or iron-deficient diets.

Options: View larger image (or click on image) Download as PowerPoint
IRP1 deficiency triggers metabolic reprogramming in mice fed high-fat or...
For 10 weeks, 5-week-old male Irp1–/– mice and WT littermates (n = 4–5 per experimental group) were provided a high-fat diet (HFD) or an iron-deficient diet (IDD). At the endpoint, the mice were euthanized, and serum, liver, and skeletal muscle samples were collected and processed for targeted metabolomics analysis. (A and B) Number of up- and down-regulated metabolites in serum, liver, and skeletal muscle of Irp1–/– versus WT on HFD (A); heatmap of detected glucogenic amino acids, ketogenic amino acids, gluconeogenesis precursors, fatty acids, and TCA cycle intermediates (B). (C and D) Number of up- and down-regulated metabolites in serum, liver, and skeletal muscle of Irp1–/– versus WT on IDD (C); heatmap of detected glucogenic amino acids, ketogenic amino acids, gluconeogenesis precursors, fatty acids, and TCA cycle intermediates (D). In B and D, log2 fold changes are indicated on the left.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts